Healio Rheumatology Current Issue

The following articles appeared in the print edition of Healio Rheumatology.

Table of Contents

• Going viral: Squaring off against social media’s medical misinformation ‘infodemic’ Rob Volansky
• COVID-19, autoimmunity and rheumatology Leonard H. Calabrese, DO
• MOC in rheumatology is 'no guarantee of anything': Debate over certification rages on Rob Volansky
• Residency Match 2021 reveals continued popularity, growth in rheumatology Rob Volansky
• ACR, medical societies reach consensus on hydroxychloroquine retinopathy Jason Laday
• EULAR releases checklist to ensure transparency in all studies using ultrasound Jason Laday
• Adalimumab, CT-P17 biosimilar exhibit comparable safety, equivalent efficacy in RA Jason Laday
• Anakinra comparable to triamcinolone for reducing gout flare pain Jason Laday
• Arthritis among most common chronic conditions for US veterans Jason Laday
• Avacopan outperforms prednisone for ANCA-associated vasculitis remission at 1 year Jason Laday
• Checkpoint inhibitor response, adverse event rate similar regardless of autoimmune disease Jason Laday
• Dysphonia, dysphagia common in COVID-related pediatric multisystem inflammation Jason Laday
• EULAR: Immunomodulatory therapy may be effective for COVID-19 subsets Jason Laday
• Fatigue, Raynaud’s top physical activity barriers for patients with scleroderma Jason Laday
• Glucocorticoid, proton pump inhibitor use linked to higher osteoporotic fracture risk in RA Jason Laday
• Heart failure linked to disease activity, inflammation in patients with psoriatic disease Jason Laday
• High-intensity vs. low-intensity strength training fails to reduce OA knee pain Jason Laday
• Moderate, high rheumatic disease activity linked to higher risk for COVID-related death Jason Laday
• Mortality rising for giant cell arteritis despite declines in general population Jason Laday
• NSAID use linked to loss of radiographic joint space width in knee OA Jason Laday
• Only 41% of Medicaid patients with lupus receive hydroxychloroquine 2 years post diagnosis Jason Laday
• Opioid use among patients with knee osteoarthritis costs US society $14B Jason Laday
• Pegloticase plus immunomodulation boosts responder rates in uncontrolled gout Jason Laday
• Pre-existing conditions, GI symptoms help distinguish MIS-C from COVID-19 pneumonia Jason Laday
• Upadacitinib matches, exceeds adalimumab for improving patient-reported outcomes in RA Jason Laday
• IL-1 inhibitors linked to ‘significant reduction’ in COVID-19 mortality Jason Laday
• Fatigue, pain top treatment priorities for patients with rheumatic disease Rob Volansky
• 'No need' to suspend immunosuppressive drugs due to COVID-19: No impact on risk outcomes Rob Volansky